Op-Ed: ‘Most Favored Nation’ Proposal Won’t Favor American Patients or New Jersey Jobs

by Chrissy Buteas, President and Chief Executive OfficerHealthCare Institute of New Jersey (HINJ) A new threat has suddenly emerged for American patients and New Jersey’s economy.  A proposal called “Most Favored Nation” (MFN) is being discussed by some policymakers in Washington.  While the intended goal is admirable – to lower healthcare costs – the actual […]

HINJ Comment Submission for Section 232 Investigation on Pharmaceutical Tariffs

Trenton, May 12, 2025 ― HINJ submitted comments to the Department of Commerce as per the Federal Register’s Notice of Request for Public Comments on Section 232 National Security Investigation of Imports of Pharmaceuticals and Pharmaceutical Ingredients.  These comments were filed in opposition to potential tariffs on pharmaceutical products and were broadly written to convey […]

HealthCare Institute of New Jersey Statement on Biomarker Testing Law

Trenton, April 23, 2025 ― Chrissy Buteas, President and Chief Executive Officer of the HealthCare Institute of New Jersey (HINJ), released the following statement concerning today’s signing into law of the state legislature’s biomarker testing bill, A4163/S3098, by Lieutenant Governor Tahesha Way. “New Jersey’s life sciences community applauds today’s enactment of this important legislation, which […]

Op-Ed: Celebrating STEM Month: New Jersey is Based on Science

by Chrissy Buteas, President and Chief Executive OfficerHealthCare Institute of New Jersey (HINJ) America is a kaleidoscope of incredible cities and states, each with its unique flavor and identity. The beauty and dry heat of Arizona, along with the magnificent Grand Canyon; beignets and coffee on a humid morning in New Orleans; the breathtaking Big […]

HealthCare Institute of New Jersey Submits Comments on PDAC Special Rule Adoption

Trenton, January 21, 2025 ― Chrissy Buteas, President and Chief Executive Officer of the HealthCare Institute of New Jersey, released the following statement concerning comments HINJ submitted to the NJ Division of Consumer Affairs’ concerning its proposed rules currently in effect and being considered for formal adoption relating to prescription drug price transparency and the […]

HealthCare Institute of New Jersey Statement on Second Round of IRA Price Controls

Trenton, January 17, 2025 ― Chrissy Buteas, President and Chief Executive Officer of the HealthCare Institute of New Jersey, released the following statement concerning the second round of government-imposed price controls on life-saving medicines announced by the Department of Health and Human Services. “There are smart and efficient ways to lower health care costs with […]

HealthCare Institute of New Jersey Statement on the FTC Report on PBMs

Trenton, January 15, 2025 ― Chrissy Buteas, President and Chief Executive Officer of the HealthCare Institute of New Jersey, released the following statement concerning yesterday’s second report issued by the Federal Trade Commission (FTC) on pharmacy benefit managers (PBMs), which found they charge significant markups for medicines treating serious conditions including cancer, multiple sclerosis, HIV, […]

HealthCare Institute of New Jersey and Organon Held “Advancing Women’s Health” Forum, Featuring First Lady Tammy Murphy, Congresswoman Bonnie Watson Coleman and Department of Human Services Commissioner Sarah Adelman

Trenton, December 17, 2024 ― The HealthCare Institute of New Jersey and Organon (www.organon.com), with premier sponsor Novartis and supporting sponsor Ferring, hosted a forum on December 16 titled “Advancing Women’s Health” – a half-day seminar highlighting New Jersey’s life sciences’ commitment to women’s health and innovating new medical advances and treatments for women.  Read […]